ArticleArthritis research & therapy2025
Efficacy and safety of tofacitinib treatment in Finnish patients with juvenile idiopathic arthritis: a real-life study.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTofacitinib (TOFA), a newly introduced Janus kinase inhibitor, has been approved for the treatment of juvenile idiopathic arthritis (JIA). In this real-life study, we describe the effectiveness of TOFA treatment as well as possible interruptions and the reasons for discontinuations among all consecutive JIA patients who started TOFA treatment.
methodsWe reported data from 53 JIA patients from the catchment area of the Helsinki University Hospital who consecutively started TOFA treatment between February 2022 and October 2024. Physicians evaluated the patients' disease activity and treatment efficacy at each visit. Disease activity was assessed using Juvenile Arthritis Disease Activity Score 10 (JADAS10).
resultsThe majority of patients (96%) started TOFA due to active disease following previous treatment failure. Both JADAS10 scores and the patients' active joint counts decreased significantly during the first 3 months of TOFA treatment. The Kaplan-Meier estimate indicated a 30% discontinuation of TOFA treatment during the 12-month follow-up period.
conclusionIn this real-life study involving 53 JIA patients, TOFA treatment was initiated consecutively and demonstrated effectiveness after 3 months, with no serious side effects reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.